|
|
35 Northeast Industrial Road
Branford, CT 6405 USA
phone:(203) 488-8201
fax:(203) 488.4863
|
|
| Symbol |
NRGN |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.neurogen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Small molecule drug candidates for pain, insomnia, inflammation, depression, and obesity. |
|
| Management |
| Stephen R. Davis, President & CEO; Srdjan (Serge) Stankovic, M.D., M.S.P.H., Executive Vice-President & Chief Development Officer; Thomas A. Pitler, Ph.D.,Senior Vice-President & Chief Business and Financial Officer; Kenneth J. Sprenger, M.D., M.B.B.Ch., Vice-President, Clinical Development and Operations; George D. Maynard, Ph.D.Vice-President, Early Development |
| |
|
|
|
|
|
|
|
| Keywords |
| pain, insomnia, inflammation, depression, obesity, |
|
|
|
| Description |
|
Neurogen is a small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from pain, insomnia, inflammation, depression, and obesity. |
|
| Products / Services |
Neurogen has generated a portfolio of new drug programs through its fully integrated drug discovery platform.
|
|
| Technology / Differentiation |
| Neurogen's Accelerated Intelligent Drug Discovery (AIDD) system, its expertise in cellular functional assays, and its depth in medicinal chemistry are key discriminators in the Company's ability to rapidly and cost-effectively identify new drug candidates. |
|
|
| Strategy |
The Company's strategy is to advance a mix of proprietary drugs independently and, when advantageous, collaborate with pharmaceutical companies during the drug development process to obtain additional resources and to access complementary expertise.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
